Summary

The global Age-Related Macular Degeneration (AMD) Treatment Drugs market size was US$ 11270 million in 2025 and is forecast to reach a readjusted size of US$ 16520 million by 2032 with a CAGR of 5.7% during the forecast period 2026-2032.
Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.
The global Age-Related Macular Degeneration (AMD) Treatment Drugs market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis
Segment by Type
Aflibercept
Ranibizumab
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market
North America
Europe
China
Japan
Chapter Outline
Chapter 1: Report scope, segment-level executive summary (by Type, by Application) and market evolution across the short, mid and long term
Chapter 2: Quantitative analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs sales and revenue at global, regional, and country levels, highlighting market size and growth potential by region
Chapter 3: Competitive landscape of Age-Related Macular Degeneration (AMD) Treatment Drugs manufacturers (sales, revenue, pricing, market share, industry rankings, and M&A / expansion plans)
Chapter 4: by Type-based segmentation analysis (sales, revenue, pricing, and growth potential) to identify blue-ocean product segments
Chapter 5: by Application-based segmentation analysis (sales, revenue, pricing, and growth potential) to uncover high-value downstream markets
Chapter 6: Regional breakdown by company, customer, by Type and by Application (sales, revenue, and pricing for each segment)
Chapter 7: Key manufacturer profiles –company overview, Age-Related Macular Degeneration (AMD) Treatment Drugs product descriptions and specifications, revenue, gross margins, and recent developments
Chapter 8: Industry chain analysis – upstream raw materials, manufacturing links, and downstream application sectors
Chapter 9: Sales channels and distributor analysis – routes to market and key customer interfaces
Chapter 10: Market dynamics – trends, drivers, restraints, risks for manufacturers, and the impact of relevant industry policies
Chapter 11: Key findings, main takeaways, and overall conclusions of the report.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Age-Related Macular Degeneration (AMD) Treatment Drugs value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Product Scope
1.2 Age-Related Macular Degeneration (AMD) Treatment Drugs by Type
1.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2021, 2025 & 2032)
1.2.2 Aflibercept
1.2.3 Ranibizumab
1.2.4 Others
1.3 Age-Related Macular Degeneration (AMD) Treatment Drugs by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Comparison by Application (2021, 2025 & 2032)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Estimates and Forecasts (2021-2032)
1.4.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size (Value) and Growth Rate (2021-2032)
1.4.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size (Volume) and Growth Rate (2021-2032)
1.4.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price Trends (2021-2032)
1.5 Assumptions and Limitations

2 Market Size and Prospects by Region
2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region: 2021 VS 2025 VS 2032
2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Historical Market Scenario by Region (2021-2026)
2.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2021-2026)
2.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2021-2026)
2.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Estimates and Forecasts by Region (2027-2032)
2.3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Estimates and Forecasts by Region (2027-2032)
2.3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Region (2027-2032)
2.4 Major Regions and Emerging Market Analysis
2.4.1 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size and Prospects (2021-2032)
2.4.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size and Prospects (2021-2032)
2.4.3 China Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size and Prospects (2021-2032)
2.4.4 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size and Prospects (2021-2032)

3 Global Market Size by Type
3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Historical Market Review by Type (2021-2026)
3.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2021-2026)
3.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2021-2026)
3.1.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2021-2026)
3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Estimates and Forecasts by Type (2027-2032)
3.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Type (2027-2032)
3.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Type (2027-2032)
3.2.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price Forecast by Type (2027-2032)
3.3 Representative Players for Different Types of Age-Related Macular Degeneration (AMD) Treatment Drugs

4 Global Market Size by Application
4.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Historical Market Review by Application (2021-2026)
4.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2021-2026)
4.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2021-2026)
4.1.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2021-2026)
4.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Estimates and Forecasts by Application (2027-2032)
4.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Forecast by Application (2027-2032)
4.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Forecast by Application (2027-2032)
4.2.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price Forecast by Application (2027-2032)
4.3 New Sources of Growth in Age-Related Macular Degeneration (AMD) Treatment Drugs Applications

5 Competition Landscape by Players
5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Player (2021-2026)
5.2 Global Top Age-Related Macular Degeneration (AMD) Treatment Drugs Players by Revenue (2021-2026)
5.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3), based on Age-Related Macular Degeneration (AMD) Treatment Drugs revenue as of 2025
5.4 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Company (2021-2026)
5.5 Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Product Type & Application
5.7 Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Date of Entry into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans

6 Regional Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company
6.1.1.1 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026)
6.1.1.2 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026)
6.1.2 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Type (2021-2026)
6.1.3 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Application (2021-2026)
6.1.4 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company
6.2.1.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026)
6.2.1.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026)
6.2.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Type (2021-2026)
6.2.3 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Application (2021-2026)
6.2.4 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company
6.3.1.1 China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026)
6.3.1.2 China Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026)
6.3.2 China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Type (2021-2026)
6.3.3 China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Application (2021-2026)
6.3.4 China Age-Related Macular Degeneration (AMD) Treatment Drugs Major Customers
6.3.5 China Market Trends and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company
6.4.1.1 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026)
6.4.1.2 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026)
6.4.2 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Type (2021-2026)
6.4.3 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Breakdown by Application (2021-2026)
6.4.4 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Major Customers
6.4.5 Japan Market Trends and Opportunities

7 Company Profiles and Key Figures
7.1 Ionis Pharmaceuticals, Inc
7.1.1 Ionis Pharmaceuticals, Inc Company Information
7.1.2 Ionis Pharmaceuticals, Inc Business Overview
7.1.3 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.1.4 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.1.5 Ionis Pharmaceuticals, Inc Recent Development
7.2 Bausch Health Companies Inc
7.2.1 Bausch Health Companies Inc Company Information
7.2.2 Bausch Health Companies Inc Business Overview
7.2.3 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.2.4 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.2.5 Bausch Health Companies Inc Recent Development
7.3 Regeneron Pharmaceuticals Inc
7.3.1 Regeneron Pharmaceuticals Inc Company Information
7.3.2 Regeneron Pharmaceuticals Inc Business Overview
7.3.3 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.3.4 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.3.5 Regeneron Pharmaceuticals Inc Recent Development
7.4 Biogen
7.4.1 Biogen Company Information
7.4.2 Biogen Business Overview
7.4.3 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.4.4 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.4.5 Biogen Recent Development
7.5 Novartis AG
7.5.1 Novartis AG Company Information
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.5.4 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.5.5 Novartis AG Recent Development
7.6 Sanofi S.A.
7.6.1 Sanofi S.A. Company Information
7.6.2 Sanofi S.A. Business Overview
7.6.3 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.6.4 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.6.5 Sanofi S.A. Recent Development
7.7 Bayer AG
7.7.1 Bayer AG Company Information
7.7.2 Bayer AG Business Overview
7.7.3 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.7.4 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.7.5 Bayer AG Recent Development
7.8 Coherus Biosciences Inc
7.8.1 Coherus Biosciences Inc Company Information
7.8.2 Coherus Biosciences Inc Business Overview
7.8.3 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.8.4 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.8.5 Coherus Biosciences Inc Recent Development
7.9 F. Hoffmann-La Roche Ltd
7.9.1 F. Hoffmann-La Roche Ltd Company Information
7.9.2 F. Hoffmann-La Roche Ltd Business Overview
7.9.3 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.9.4 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.9.5 F. Hoffmann-La Roche Ltd Recent Development
7.10 Apellis Pharmaceuticals Inc
7.10.1 Apellis Pharmaceuticals Inc Company Information
7.10.2 Apellis Pharmaceuticals Inc Business Overview
7.10.3 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.10.4 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.10.5 Apellis Pharmaceuticals Inc Recent Development
7.11 AbbVie
7.11.1 AbbVie Company Information
7.11.2 AbbVie Business Overview
7.11.3 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.11.4 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.11.5 AbbVie Recent Development
7.12 Pfizer Inc.
7.12.1 Pfizer Inc. Company Information
7.12.2 Pfizer Inc. Business Overview
7.12.3 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.12.4 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.12.5 Pfizer Inc. Recent Development
7.13 Amgen Inc.
7.13.1 Amgen Inc. Company Information
7.13.2 Amgen Inc. Business Overview
7.13.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.13.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.13.5 Amgen Inc. Recent Development
7.14 Samsung Bioepis
7.14.1 Samsung Bioepis Company Information
7.14.2 Samsung Bioepis Business Overview
7.14.3 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
7.14.4 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Products Offered
7.14.5 Samsung Bioepis Recent Development

8 Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Cost Analysis
8.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
8.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Industrial Chain Analysis

9 Marketing Channels, Distributors and Customers
9.1 Marketing Channels
9.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors List
9.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Customers

10 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Dynamics
10.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Trends
10.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
10.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Challenges
10.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Restraints

11 Research Findings and Conclusion

12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (US$ Million) Growth Rate by Type (2021, 2025 & 2032)
Table 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (US$ Million) Comparison by Application (2021, 2025 & 2032)
Table 3. Global Market Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size (US$ Million) by Region:2021 VS 2025 VS 2032
Table 4. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Region (2021-2026)
Table 5. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2021-2026)
Table 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) Market Share by Region (2021-2026)
Table 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Region (2021-2026)
Table 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) Forecast by Region (2027-2032)
Table 9. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share Forecast by Region (2027-2032)
Table 10. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) Forecast by Region (2027-2032)
Table 11. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share Forecast by Region (2027-2032)
Table 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (K Dose) & (2021-2026)
Table 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Type (2021-2026)
Table 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (US$ Million) & (2021-2026)
Table 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (US$/Dose) & (2021-2026)
Table 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (K Dose) & (2027-2032)
Table 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (US$ Million) & (2027-2032)
Table 18. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (US$/Dose) & (2027-2032)
Table 19. Representative Players of Each Type
Table 20. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (K Dose) & (2021-2026)
Table 21. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Application (2021-2026)
Table 22. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (US$ Million) & (2021-2026)
Table 23. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (US$/Dose) & (2021-2026)
Table 24. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (K Dose) & (2027-2032)
Table 25. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (US$ Million) & (2027-2032)
Table 26. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (US$/Dose) & (2027-2032)
Table 27. New Sources of Growth in Age-Related Macular Degeneration (AMD) Treatment Drugs Applications
Table 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (K Dose) & (2021-2026)
Table 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Company (2021-2026)
Table 30. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (US$ Million) & (2021-2026)
Table 31. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Company (2021-2026)
Table 32. Global Age-Related Macular Degeneration (AMD) Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Treatment Drugs as of 2025)
Table 33. Global Market Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Company (US$/Dose) & (2021-2026)
Table 34. Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Product Type & Application
Table 36. Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Date of Entry into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026) & (K Dose)
Table 39. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2021-2026)
Table 40. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 41. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2021-2026)
Table 42. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2021-2026) & (K Dose)
Table 43. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2021-2026)
Table 44. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2021-2026) & (K Dose)
Table 45. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2021-2026)
Table 46. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026) & (K Dose)
Table 47. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2021-2026)
Table 48. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 49. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2021-2026)
Table 50. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2021-2026) & (K Dose)
Table 51. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2021-2026)
Table 52. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2021-2026) & (K Dose)
Table 53. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2021-2026)
Table 54. China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026) & (K Dose)
Table 55. China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2021-2026)
Table 56. China Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 57. China Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2021-2026)
Table 58. China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2021-2026) & (K Dose)
Table 59. China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2021-2026)
Table 60. China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2021-2026) & (K Dose)
Table 61. China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2021-2026)
Table 62. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Company (2021-2026) & (K Dose)
Table 63. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Company (2021-2026)
Table 64. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 65. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Company (2021-2026)
Table 66. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2021-2026) & (K Dose)
Table 67. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2021-2026)
Table 68. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2021-2026) & (K Dose)
Table 69. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2021-2026)
Table 70. Ionis Pharmaceuticals, Inc Company Information
Table 71. Ionis Pharmaceuticals, Inc Description and Business Overview
Table 72. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 73. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 74. Ionis Pharmaceuticals, Inc Recent Development
Table 75. Bausch Health Companies Inc Company Information
Table 76. Bausch Health Companies Inc Description and Business Overview
Table 77. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 78. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 79. Bausch Health Companies Inc Recent Development
Table 80. Regeneron Pharmaceuticals Inc Company Information
Table 81. Regeneron Pharmaceuticals Inc Description and Business Overview
Table 82. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 83. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 84. Regeneron Pharmaceuticals Inc Recent Development
Table 85. Biogen Company Information
Table 86. Biogen Description and Business Overview
Table 87. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 88. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 89. Biogen Recent Development
Table 90. Novartis AG Company Information
Table 91. Novartis AG Description and Business Overview
Table 92. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 94. Novartis AG Recent Development
Table 95. Sanofi S.A. Company Information
Table 96. Sanofi S.A. Description and Business Overview
Table 97. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 99. Sanofi S.A. Recent Development
Table 100. Bayer AG Company Information
Table 101. Bayer AG Description and Business Overview
Table 102. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 104. Bayer AG Recent Development
Table 105. Coherus Biosciences Inc Company Information
Table 106. Coherus Biosciences Inc Description and Business Overview
Table 107. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 109. Coherus Biosciences Inc Recent Development
Table 110. F. Hoffmann-La Roche Ltd Company Information
Table 111. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 112. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 114. F. Hoffmann-La Roche Ltd Recent Development
Table 115. Apellis Pharmaceuticals Inc Company Information
Table 116. Apellis Pharmaceuticals Inc Description and Business Overview
Table 117. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 119. Apellis Pharmaceuticals Inc Recent Development
Table 120. AbbVie Company Information
Table 121. AbbVie Description and Business Overview
Table 122. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 124. AbbVie Recent Development
Table 125. Pfizer Inc. Company Information
Table 126. Pfizer Inc. Description and Business Overview
Table 127. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 129. Pfizer Inc. Recent Development
Table 130. Amgen Inc. Company Information
Table 131. Amgen Inc. Description and Business Overview
Table 132. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 134. Amgen Inc. Recent Development
Table 135. Samsung Bioepis Company Information
Table 136. Samsung Bioepis Description and Business Overview
Table 137. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 139. Samsung Bioepis Recent Development
Table 140. Production Base and Market Concentration Rate of Raw Material
Table 141. Key Suppliers of Raw Materials
Table 142. Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors List
Table 143. Age-Related Macular Degeneration (AMD) Treatment Drugs Customers List
Table 144. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Trends
Table 145. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
Table 146. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Challenges
Table 147. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources

List of Figures
Figure 1. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Picture
Figure 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (US$ Million) by Type (2021, 2025 & 2032)
Figure 3. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type in 2025 & 2032
Figure 4. Aflibercept Product Picture
Figure 5. Ranibizumab Product Picture
Figure 6. Others Product Picture
Figure 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (US$ Million) by Application (2021, 2025 & 2032)
Figure 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application in 2025 & 2032
Figure 9. Hospital Pharmacy Examples
Figure 10. Retail Pharmacy Examples
Figure 11. Online Pharmacy Examples
Figure 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, (US$ Million), 2021 VS 2025 VS 2032
Figure 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Growth Rate (2021-2032) & (US$ Million)
Figure 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) Growth Rate (2021-2032)
Figure 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price Trends Growth Rate (2021-2032) & (US$/Dose)
Figure 16. Age-Related Macular Degeneration (AMD) Treatment Drugs Report Years Considered
Figure 17. Global Market Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size (US$ Million) by Region:2021 VS 2025 VS 2032
Figure 18. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region: 2021 VS 2025
Figure 19. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) Growth Rate (2021-2032)
Figure 21. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 22. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) Growth Rate (2021-2032)
Figure 23. China Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 24. China Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) Growth Rate (2021-2032)
Figure 25. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 26. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) Growth Rate (2021-2032)
Figure 27. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Type (2021-2026)
Figure 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Type (2027-2032)
Figure 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Type (2027-2032)
Figure 30. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Application (2021-2026)
Figure 31. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application in 2021 & 2025
Figure 32. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Application (2027-2032)
Figure 33. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Application (2027-2032)
Figure 34. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Company (2025)
Figure 35. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Company (2025)
Figure 36. Global 5 Largest Age-Related Macular Degeneration (AMD) Treatment Drugs Players Market Share by Revenue in Age-Related Macular Degeneration (AMD) Treatment Drugs: 2021 & 2025
Figure 37. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 38. Manufacturing Cost Structure of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 39. Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 40. Age-Related Macular Degeneration (AMD) Treatment Drugs Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed